ISOLASI DAN AKTIVITAS ANTIKANKER PINOSTROBIN DARI TEMU KUNCI (Kaempferia pandurata Roxb) TERHADAP FIBROSARKOMA MENCIT HASIL INDUKSI BENZOPIREN
on
Authors:
Oka Adi Parwata, Sukardiman Sukardiman, Alit Widhiartini
Abstract:
“Induction of apoptosis and antiangiogenesis effects of Pinostrobin from Kaempferia pandurata Roxb against Fibrosarkoma mice induced with benzopiren have been investigated. Examination begins with taking tissue of fibrosarcoma in mice infected and weighing the fibrosarcoma obtained. Fibrosarcoma tissues were then stored in 10 % formalin. Weighing results showed that pinostrobin oral concentration of 80 mg/kg can inhibit 68.62 % growth of fibrosarcoma. It was also shown that cancer drug (positive control) resulted in 95.95 % inhibition compared to the negative control. This means pinostrobin can potentially be developed as a cancer chemotherapy drug. Patohystology analysis of the fibrosarcoma tissue with HE staining on light microscope with 400x magnification showed many chromatins (polychromatin) which proved the damage caused by the fibrosarcoma cells.”
Keywords
Keyword Not Available
Downloads:
Download data is not yet available.
References
References Not Available
PDF:
https://jurnal.harianregional.com/jchem/full-11766
Published
2014-07-01
How To Cite
ADI PARWATA, Oka; SUKARDIMAN, Sukardiman; WIDHIARTINI, Alit. ISOLASI DAN AKTIVITAS ANTIKANKER PINOSTROBIN DARI TEMU KUNCI (Kaempferia pandurata Roxb) TERHADAP FIBROSARKOMA MENCIT HASIL INDUKSI BENZOPIREN.Jurnal Kimia (Journal of Chemistry), [S.l.], july 2014. ISSN 2599-2740. Available at: https://jurnal.harianregional.com/jchem/id-11766. Date accessed: 02 Jun. 2025. doi:https://doi.org/10.24843/JCHEM.2014.v08.i02.p16.
Citation Format
ABNT, APA, BibTeX, CBE, EndNote - EndNote format (Macintosh & Windows), MLA, ProCite - RIS format (Macintosh & Windows), RefWorks, Reference Manager - RIS format (Windows only), Turabian
Issue
Vol. 8, No. 2 Juli 2014
Section
Articles
Copyright
This work is licensed under a Creative Commons Attribution 4.0 International License
Discussion and feedback